Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan for Vasospasm in aSAH (CONSCIOUS-3)
NCT00940095Phase 3Terminated
- Sponsor
- Idorsia
- Start
- Jul 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of clazosentan in aneurysmal subarachnoid hemorrhage (SAH) (3 arms), sponsored by Idorsia. Primary endpoint: Cerebral vasospasm-related morbidity and mortality of all-causes at 6 weeks. Started Jul 2009; status: terminated.
02
Drugs
clazosentan
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT00940095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940095.